Trade AstraZeneca ^AZN

FDA delays ruling on AstraZeneca drug after negative adcomm vote

William Blair Investment Management LLC Raises Stake in Astrazeneca Plc $AZN - Stock Observer

AstraZeneca falls 7% as Q4 net profit declines 23%; here's a trading strategy for the pharma stock

3,842 Shares in Astrazeneca Plc $AZN Acquired by M3 Wealth Management LLC - Stock Observer

UK Value Opportunities: Serica Energy Among 3 Stocks Priced Below Intrinsic Estimates

Preparing for a time when living to age 120 is commonplace | AfricaPulse.com

Bleakley Financial Group LLC Has $15.34 Million Holdings in Astrazeneca Plc $AZN - Stock Observer

Hantz Financial Services Inc. Buys 39,244 Shares of Astrazeneca Plc $AZN - Stock Observer

Main Street Research LLC Makes New Investment in Astrazeneca Plc $AZN - Stock Observer

GPS Wealth Strategies Group LLC Decreases Stock Holdings in Astrazeneca Plc $AZN - Zolmax

AstraZeneca's Camizestrant: EU Approves Game-Changing Breast Cancer Pill Amid US Concerns, ETPharma

Insider Sell: Mani Sharma Sells Shares of AstraZeneca PLC

FDA Approves AstraZeneca And Daiichi's Datroway For Treating Metastatic Breast Cancer

AstraZeneca (AZN) Gains U.S. Approval for Datroway in Breast Cancer Treatment

AstraZeneca Breast Cancer Drug Recommended for Approval by EU Regulator | Morningstar

AstraZeneca, Daiichi Sankyo's Datroway Gets Approval In US For Treatment Of Breast Cancer

AZN Receives Positive EU Approval Recommendation for Enhertu

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates | Morningstar

AstraZeneca (AZN) Showcases Promising Clinical Data at ASCO Annual Meeting

AstraZeneca's Camizestrant Receives Positive Opinion from EMA

EU regulator recommends positive opinion of AstraZeneca's experimental breast cancer drug

Vestmark Advisory Solutions Inc. Acquires 93,186 Shares of Astrazeneca Plc $AZN - Stock Observer

Keudell Morrison Wealth Management Buys New Position in Astrazeneca Plc $AZN - Stock Observer

Astrazeneca (NYSE:AZN) Receives "Sell" Rating from Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft Reaffirms Sell Rating for Astrazeneca (NYSE:AZN) - Zolmax

Global Retirement Partners LLC Has $9.85 Million Stock Position in Astrazeneca Plc $AZN - Daily Political

25,822 Shares in AstraZeneca PLC $AZNCF Acquired by Burling Wealth Partners LLC - Stock Observer

How VEPPANU Approval Frames Expectations For AstraZeneca's Camizestrant In ESR1 Disease

Compugen Ltd. (NASDAQ:CGEN) Q1 2026 Earnings Call Transcript

Astrazeneca Plc (NYSE:AZN) Receives $205.33 Average Target Price from Analysts - Zolmax

Harvest Portfolios Group Inc. Sells 39,131 Shares of Astrazeneca Plc $AZN

Astrazeneca Plc $AZN Shares Acquired by Envestnet Portfolio Solutions Inc.

Gabelli Funds LLC Cuts Stock Holdings in Astrazeneca Plc $AZN - Stock Observer

Ultra-high tumor mutation burden breast cancer: genomic profiling and real-world immunotherapy results

AstraZeneca, Roche join forces to boost AI-based cancer pathology across Asia

Treatment strategies in giant cell arteritis and polymyalgia rheumatica: beyond glucocorticoids

Astrazeneca Plc $AZN Shares Acquired by ProShare Advisors LLC - Stock Observer

Northwestern Mutual Wealth Management Co. Increases Stake in Astrazeneca Plc $AZN - Daily Political

AstraZeneca (AZN) Faces Potential Market Shifts Amid Trump's Prescription Plan

AstraZeneca Wins FDA Approval for $5 Billion Blood Pressure Drug

AstraZeneca (AZN) Receives US Approval for Innovative Hypertension Treatment

AstraZeneca (AZN) Gains Approval for New Hypertension Drug Baxfendy

North American Morning Briefing: Stock Futures Slip Amid Mideast, Inflation Pessimism | Morningstar

Dow Jones Top Company Headlines at 5 AM ET: Anglo American to Sell Australian Steelmaking Coal Assets for Up to $3.875 Billion | AstraZeneca ... | Morningstar

Dow Jones Top Company Headlines at 3 AM ET: Anglo American to Sell Steelmaking Coal Assets to Dhilmar for Up to $3.875 Billion | AstraZeneca ... | Morningstar

AstraZeneca wins US approval for first-in-class blood pressure drug and expands cancer treatment Enhertu

AstraZeneca: FDA Approves Enhertu For Two New Indications

AstraZeneca's New Blood Pressure Drug Baxfendy Approved by FDA, ETPharma

AstraZeneca's blood pressure drug wins US approval

AstraZeneca Collaborates with Roche Diagnostics Asia Pacific to Help Accelerate Sustainable Ecosystem for Advanced Pathology in Breast and Lung Cancer

Sensorion Appoints Fred Chereau as Chief Executive Officer | Morningstar

New hypertension option as Astrazeneca's Baxfendy wins FDA nod | BioWorld

Supreme Court rejects Big Pharma appeals challenging negotiated drug prices in Medicare | News Express Nigeria

Ghana Hypertension Day Exposes Dangerous Treatment Gap | NewsGhana

Independent Advisor Alliance Sells 3,393 Shares of Astrazeneca Plc $AZN - Zolmax

Is It Too Late To Consider AstraZeneca (LSE:AZN) After A 34% One Year Rally?

Astrazeneca (NYSE:AZN) Earns Buy Rating from JPMorgan Chase & Co. - Daily Political

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer

Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial

Breast Cancer Treatment from Daiichi Sankyo, AstraZeneca Approved in U.S. | Morningstar

Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer | Morningstar

AstraZeneca (AZN) Sees Leadership Changes at FDA

Bristol Myers Squibb turns to China's Hengrui to replenish pipeline

ULTOMIRIS Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

Expert recommendations for PIK3CA testing in HR+/HER2− locally advanced and metastatic breast cancer

Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons

TR/CC CRB Excess Return Today - Live TRCCRB Index - Investing.com CA

Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study

'Pfizer and AstraZeneca were ABANDONED, yet…': Sen Johnson drops bombshell on COVID vaccine injuries - The Economic Times Video | ET Tv

AZN Shows Promising Results in Phase III Trial for Muscle-Invasive Bladder Cancer

AZN: Promising Phase III Trial Results for Imfinzi in Bladder Cancer Treatment

AstraZeneca's Imfinzi Shows Promising Survival Benefits in Bladder Cancer Trial, ETPharma

JPMorgan Chase & Co. Reiterates Buy Rating for Astrazeneca (NYSE:AZN) - Stock Observer

AstraZeneca Says Imfinzi Combination Improved Survival In Phase III Bladder Cancer Trial

Omeros Corp (OMER) Q1 2026 Earnings Call Highlights: Strong YARTEMLEA Launch and Strategic ...

AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41

Health: AstraZeneca's Imfinzi with pre-surgery drug boosts survival in bladder cancer trial

Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial

Ex vivo drug screening and clustering of bladder cancers for pre-clinical treatment prediction

Innate Pharma Reports First Quarter 2026 Business Update and Financial Results

Innate Pharma présente l'avancée de son portefeuille et ses résultats financiers du premier trimestre 2026

In the clinic for May 13, 2026 | BioWorld

Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial

Implementing AI in workflows: One step at a time

UK junior minister Miatta Fahnbulleh resigns, urges PM Starmer to set exit timetable

AstraZeneca PLC (LON:AZN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - Daily Political

AstraZeneca PLC (AZN) Stock Falls as FDA Panel Votes Against New Cancer Drug

Early FMISO PET changes as exploratory predictors of immune checkpoint inhibitor response in advanced lung cancer: a pilot study

PRIMECAP Management's Strategic Moves: AstraZeneca PLC Exits with a -2.57% Impact

Cellectis Reports Financial Results for the First Quarter 2026

Cellectis publie ses résultats financiers du premier trimestre 2026

CDT Equity Advances AstraZeneca PLC (AZN)'s AZD5904 Into PCT Patent Protection Stage

Drug companies involved in TrumpRx boosted lobbying by 23% ahead of program's launch

Astrazeneca Plc $AZN Position Boosted by NewEdge Wealth LLC

Mitsubishi UFJ Asset Management Co. Ltd. Raises Holdings in Astrazeneca Plc $AZN - Stock Observer

Positron-emission tomography as a predictor of response to first-line cyclin-dependent kinase 4/6 inhibitors in patients with metastatic ER-positive HER2-negative breast cancer